This phase 3 trial is comparing the effectiveness of using two targeted therapies (Pembrolizumab and Olaparib) for the first line treatment of metastatic Squamous Non-small Cell Lung Cancer .
This trial is treating patients with Metastatic Squamous Non-Small-Cell Lung Cancer.
This is a systemic therapy.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
- MK-7339-008 KEYLYNK-008 2018-004721-88 7339-008
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This trial consists of two parts: the Induction and Maintenance phase. All patients eligible to participate in this trial will receive intravenous administration of Pembrolizumab and chemotherapy drugs (carboplatin and paclitaxel or nab-paclitaxel) on Day 1 of 4 x 21 day cycles. People eligible to participate in the Maintenance phase will either receive intravenous administration of Pembrolizumab on Day 1 of each 21 day cycle and orally administered Olaparib twice daily, or Pembrolizumab and an orally administered placebo. Maintenance will continue for up to 31 cycles.
Recruiting Hospitals Read More